• 1
    Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996; 335: 9197.
  • 2
    Barlogie B. High-dose therapy and innovative approaches to treatment of multiple myeloma. Semin Hematol. 2001; 38: 2127.
  • 3
    Cunningham D, Paz-Ares L, Milan S, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol. 1994; 12: 759763.
  • 4
    Harousseau J, Attal M. The role of stem cell transplantation in multiple myeloma. Blood Rev. 2002; 16: 245253.
  • 5
    Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002; 99: 731735.
  • 6
    Alexanian R, Weber D, Giralt S, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001; 27: 10371043.
  • 7
    Shimoni A, Smith TL, Aleman A, et al. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant. 2001; 27: 821828.
  • 8
    Alexanian R, Balcerzak S, Bonnet J, et al. Prognostic factors in multiple myeloma. Cancer. 1975; 36: 11921201.
  • 9
    Dimopoulos MA, Alexanian R, Przepiorka D, et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood. 1993; 82: 23242328.
  • 10
    Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998; 102: 11151123.
  • 11
    Anderson KC, Kyle RA, Dalton WS, et al. Multiple myeloma: new insights and therapeutic approaches. Hematology (Am Soc Hematol Educ Program). 2000: 147165.
  • 12
    Anagnostopoulos A, Aleman A, Yang Y, et al. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone Marrow Transplant. 2004; 33: 623628.
  • 13
    Cunningham D, Powles R, Malpas J, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol. 1998; 102: 495502.
  • 14
    Majolino I, Vignetti M, Meloni G, et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo. Haematologica. 1999; 84: 844852.
  • 15
    Bjorkstrand B, Svensson H, Goldschmidt H, et al. EBMT Registry results of autologous bone marrow and peripheral blood stem cell transplantation [abstract]. Presented at the VII International Multiple Myeloma Workshop, Stockholm, Sweden, September 15, 1999.
  • 16
    Lahuerta JJ, Martinez-Lopez J, Grande C, et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol. 2000; 109: 138147.
  • 17
    Barlogie BM, Shaughnessy J, Sawyer J, et al. Total Therapy II (TTII) for newly diagnosed multiple myeloma (MM): preliminary data on feasibility and efficacy in the first 231 enrolled patients; comparison with predecessor trial Total Therapy I (TTI) (N = 231) [abstract]. Blood. 2001; 98 Suppl 1: 352a.
  • 18
    Donato M, Weber D, Alexanian R, et al. High dose topotecan melphalan and cyclophosphamide (TMC): a new regimen for autologous transplantation in multiple myeloma [abstract]. Blood. 2000; 96 Suppl 1: 798a.
  • 19
    Giralt S, Champlin R, Alexanian R, et al. Results of a Phase I/II trial with 166Ho-DOTMP plus high dose chemotherapy in patients with multiple myeloma [abstract]. Presented at the VIII International Multiple Myeloma Workshop, Banff, Alberta, Canada, May 4–8, 2001.